Roche trumpeted a “major advancement” in the retinal space with the approval of its eye drug Susvimo last October, touting it as a more manageable option for patients with wet age-related macular degeneration. However, safety concerns leave some physicians hesitant. While most ophthalmologists have heard of Susvimo — 86%, according to the latest Spherix survey of 76 doctors — only one in ten believe the benefits completely outweigh the risks.
